OGN – organon & co. (US:NASDAQ)
Stock Stats
News
Organon accelerates Women's Health progress across Asia Pacific with 2026 Her Health Grants
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age
Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility [Seeking Alpha]
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
Organon & Co. (NYSE:OGN) had its price target raised by analysts at Barclays PLC from $7.50 to $8.00. They now have an "underweight" rating on the stock.
Form 4 Organon & Co. For: Mar 31 Filed by: Drinane Juliana Papa
Form 4 Organon & Co. For: Mar 31 Filed by: Arjona Ferreira Juan Camilo
Form 4 Organon & Co. For: Mar 31 Filed by: Karp Daniel
Form 4 Organon & Co. For: Mar 31 Filed by: Stahler Rachel A
Form 4 Organon & Co. For: Mar 31 Filed by: WALSH MATTHEW M
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.